Literature DB >> 20731701

VEGF and nitric oxide synthase immunoexpression in Down's syndrome amniotic fluid stem cells.

Eleonora Salvolini1, Monia Orciani, Guendalina Lucarini, Arianna Vignini, Andrea Luigi Tranquilli, Roberto Di Primio.   

Abstract

BACKGROUND: It has been previously observed that the amniotic fluid obtained from Down's syndrome (DS) pregnancies showed lower levels of vascular endothelial growth factor (VEGF) and higher levels of nitric oxide (NO) with respect to the controls, suggesting the presence of an imbalance between placental vascularization and altered endothelial function. The aim of our study was to evaluate the immunohistochemical expression and localization of VEGF and nitric oxide synthase (NOS) isoforms in cultured amniotic fluid mesenchymal stem cells (AF-MSCs) isolated from normal euploid pregnancies and pregnancies complicated by trisomy 21. In addition, we measured the VEGF and NO content in cell culture supernatants to analyse their production by AF-MSCs.
MATERIALS AND METHODS: AF-MSCs were obtained from women with foetal DS and controls matched for age and gestation, and expanded in culture. The cells were then evaluated for the immunohistochemical expression of VEGF and NOS isoforms, as well as for the release of VEGF and NO.
RESULTS: Our analyses showed that both the VEGF expression and production were significantly lower in DS-AF-MSCs with respect to the controls. As regards NOS, immunohistochemical expression of eNOS was significantly reduced in DS-AF-MSCs, whereas the nNOS and iNOS were similarly immunoexpressed in both groups of cells. Moreover, we observed that the NO content was significantly higher in medium derived by DS-AF-MSCs.
CONCLUSIONS: Our study shows, for the first time, the differences between AF-MSCs isolated from control and trisomy 21 pregnancies and suggest an involvement of NO and VEGF in the physiopathological mechanisms associated with DS pregnancy.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731701     DOI: 10.1111/j.1365-2362.2010.02370.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  New miRNAs network in human mesenchymal stem cells derived from skin and amniotic fluid.

Authors:  R Lazzarini; G Sorgentoni; M Caffarini; M A Sayeed; F Olivieri; R Di Primio; M Orciani
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

2.  Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors.

Authors:  M Orciani; S Davis; G Appolloni; R Lazzarini; M Mattioli-Belmonte; R A Ricciuti; M Boscaro; R Di Primio; G Arnaldi
Journal:  Cancer Gene Ther       Date:  2014-12-19       Impact factor: 5.987

3.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.

Authors:  Faycal Guedj; Ashley E Siegel; Jeroen L A Pennings; Fatimah Alsebaa; Lauren J Massingham; Umadevi Tantravahi; Diana W Bianchi
Journal:  Am J Hum Genet       Date:  2020-10-23       Impact factor: 11.025

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.